<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020864</url>
  </required_header>
  <id_info>
    <org_study_id>09.08</org_study_id>
    <nct_id>NCT01020864</nct_id>
  </id_info>
  <brief_title>Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer</brief_title>
  <acronym>CECAVI</acronym>
  <official_title>Phase II Trial of Cetuximab in Combination With Chemotherapy (Carboplatin and Navelbine) for Patients With Platinum-resistant Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, multicenter phase II study. The purpose is to demonstrate the efficacy of&#xD;
      cetuximab in combination with carboplatin and vinorelbine as second line treatment in&#xD;
      patients with recurrent or metastatic head and neck cancer who have progressed during or&#xD;
      after treatment with first line cisplatinum.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between response and evolvement in tumor biology markers.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.&#xD;
Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab 500 mg/m² i.v. day 1, every 2nd week</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC = 3 i.v. day 1, every 21nd week</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine 25 mg/m² i.v. day 1, every 2nd week</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified squamous cell carcinoma of the head and neck where curatively&#xD;
             intended local treatment is not possible.&#xD;
&#xD;
          -  Measurable or non-measurable disease.&#xD;
&#xD;
          -  Disease progression during or after first line palliative chemotherapy with&#xD;
             cisplatinum or patients with recurrence &lt; 6 months after primary concomitant&#xD;
             chemo-radiotherapy with cisplatinum.&#xD;
&#xD;
          -  WHO Performance Status 0-2.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Neutrophil count (ANC) ≥ 1.5 x 10^9/l and platelets ≥ 100 x 10^9/l.&#xD;
&#xD;
          -  Normal liver function with bilirubin &lt; 1.5 x UNL (Upper Normal Limit), no UNL for ALAT&#xD;
             with liver metastases.&#xD;
&#xD;
          -  Creatinin clearance ≥ 50 ml/min.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other active malignant disease.&#xD;
&#xD;
          -  Patients who are considered unable to follow the treatment plan or follow-up visits.&#xD;
&#xD;
          -  Other serious disease (e.g. severe heart disease, myocardial infarction (MI) within 1&#xD;
             year, active infection).&#xD;
&#xD;
          -  Any condition or treatment which after the opinion of the investigator may expose the&#xD;
             patient to a risk or may influence the purpose of the trial.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Known hypersensitivity towards one or more of the components of the treatment.&#xD;
&#xD;
          -  Prior treatment with either cetuximab or other inhibitors of EGFR.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2009</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Platinum-resistent head and neck cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Navelbine</keyword>
  <keyword>Phase II trial</keyword>
  <keyword>Combination chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

